Bhekisisa news story
— As South Africa prepares to roll out lenacapavir (LEN) — a twice-yearly HIV prevention injection — at 360 government clinics, another jab, long-acting cabotegravir (CAB-LA), has made a quiet exit.
— CAB-LA stalled mainly because of cost: at roughly $180 (R2 900) per person per year, it is about four times more expensive than generic lenacapavir, and a PEPFAR donation that could have changed the picture was frozen by the Trump administration’s 2025 aid stop-work orders before a single dose arrived.
— But advocates say the training, systems and real-world data built around CAB-LA were not wasted — they now form the foundation on which lenacapavir’s roll-out will be built.
Read the full news story here.
Source : Bhekisisa
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.